Literature DB >> 3323164

Tissue distribution of roxithromycin.

E Bergogne-Bérézin1.   

Abstract

As tissue distribution studies have become increasingly important aspects of the assessment of new antimicrobials, roxithromycin distribution has been evaluated in experimental models and in human tissues and body fluids. High levels were achieved in respiratory tract tissues and fluids and in the male and female genital tract. In most experiments the local concentrations of roxithromycin were as high as that in serum, reaching 4-6 mg/l (or mg/kg) or more. These high levels were generally stable and an equilibrium was reached between central and extra-vascular compartments. These data provide important information which may be clinically relevant.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3323164     DOI: 10.1093/jac/20.suppl_b.113

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

Review 1.  Formulary management of macrolide antibiotics.

Authors:  D R Guay
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 2.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 3.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Helicobacter pylori: the place of the new macrolides in the eradication of the bacteria in peptic ulcer disease.

Authors:  A Burette; Y Glupczynski
Journal:  Infection       Date:  1995       Impact factor: 3.553

5.  In vitro susceptibilities of Bartonella henselae, B. quintana, B. elizabethae, Rickettsia rickettsii, R. conorii, R. akari, and R. prowazekii to macrolide antibiotics as determined by immunofluorescent-antibody analysis of infected Vero cell monolayers.

Authors:  T J Ives; P Manzewitsch; R L Regnery; J D Butts; M Kebede
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

Review 6.  Macrolide antibiotics in paediatric infectious diseases.

Authors:  D R Guay
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

7.  Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

8.  A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors:  W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

9.  In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii.

Authors:  H R Chang; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

Review 10.  Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  R A Young; J P Gonzalez; E M Sorkin
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.